U.S. FDA Panel Backs Pfizer’s RSV Vaccine for Defending Infants

(Reuters) – Advisers to the U.S. Meals and Drug Administration on Thursday backed the security and effectiveness of Pfizer Inc’s experimental respiratory syncytial virus (RSV) vaccine, boosting its probabilities of changing into the primary accessible maternal shot to guard infants from the sickness.

The FDA’s advisory committee voted unanimously that accessible knowledge supported the vaccine’s efficacy for giving the shot to ladies of their second or third trimesters of being pregnant to stop decrease respiratory tract an infection and extreme illness in infants as much as 6 months of age.

The professional panel voted 10-4 that the information additionally helps the security of the vaccine for that affected person inhabitants, paving the way in which for seemingly U.S. approval.

(Reporting by Mariam Sunny and Raghav Mahobe in Bengaluru; Enhancing by Invoice Berkrot)

Copyright 2023 Thomson Reuters.

Source link